LT3411021T - Sakubitrilo ir valsartano derinio naujas panaudojimas - Google Patents

Sakubitrilo ir valsartano derinio naujas panaudojimas

Info

Publication number
LT3411021T
LT3411021T LTEPPCT/IB2017/050573T LTIB2017050573T LT3411021T LT 3411021 T LT3411021 T LT 3411021T LT IB2017050573 T LTIB2017050573 T LT IB2017050573T LT 3411021 T LT3411021 T LT 3411021T
Authority
LT
Lithuania
Prior art keywords
sacubitrile
valsartan
combination
new use
new
Prior art date
Application number
LTEPPCT/IB2017/050573T
Other languages
English (en)
Inventor
Fabian CHEN
Surya Prakash AYALASOMAYAJULA
Christopher Bush
Masha BERKHIN
Gesine Winzenburg
Bernd TRUEBY
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3411021(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3411021T publication Critical patent/LT3411021T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/IB2017/050573T 2016-02-03 2017-02-02 Sakubitrilo ir valsartano derinio naujas panaudojimas LT3411021T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16154153 2016-02-03
US201662293005P 2016-02-09 2016-02-09
US201662393163P 2016-09-12 2016-09-12
PCT/IB2017/050573 WO2017134600A1 (en) 2016-02-03 2017-02-02 New use of a combination of sacubitril and valsartan

Publications (1)

Publication Number Publication Date
LT3411021T true LT3411021T (lt) 2025-08-25

Family

ID=55299378

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2017/050573T LT3411021T (lt) 2016-02-03 2017-02-02 Sakubitrilo ir valsartano derinio naujas panaudojimas

Country Status (19)

Country Link
US (3) US20190054069A1 (lt)
EP (3) EP3411018A1 (lt)
JP (4) JP6810152B2 (lt)
KR (1) KR102805176B1 (lt)
CN (1) CN108601741B (lt)
AU (2) AU2017215530B2 (lt)
CA (1) CA3010778C (lt)
DK (1) DK3411021T3 (lt)
ES (1) ES3036922T3 (lt)
FI (1) FI3411021T3 (lt)
HR (1) HRP20250913T1 (lt)
HU (1) HUE072182T2 (lt)
IL (1) IL260955A (lt)
LT (1) LT3411021T (lt)
PL (1) PL3411021T3 (lt)
PT (1) PT3411021T (lt)
RS (1) RS67127B1 (lt)
SI (1) SI3411021T1 (lt)
WO (2) WO2017134597A1 (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3036922T3 (en) 2016-02-03 2025-09-25 Novartis Ag New use of a combination of sacubitril and valsartan
US20200276129A1 (en) * 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
EP3840746A1 (en) * 2018-08-23 2021-06-30 Novartis AG New pharmaceutical use for the treatment of heart failure
KR102545274B1 (ko) * 2020-02-26 2023-06-20 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
WO2021172960A1 (ko) * 2020-02-26 2021-09-02 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
KR20220091767A (ko) * 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
US20240100088A1 (en) * 2021-01-31 2024-03-28 Alexion Pharmaceuticals, Inc. Novel formulation for treating copper metabolism-associated diseases or disorders
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2023284724A1 (zh) * 2021-07-12 2023-01-19 上海博志研新药物技术有限公司 沙库巴曲缬沙坦钠缓释组合物、其制备方法及应用
CN116687921A (zh) * 2023-06-14 2023-09-05 宁波大学 沙库巴曲缬沙坦类物质在制备神经毒性和认知障碍类药物的应用
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
BR0211117A (pt) * 2001-07-16 2004-06-22 Astrazeneca Ab Tablete multiparticulado, processo para a manufatura e uso do mesmo, e, método e tratamento de distúrbios gastrointestinais
DK1467728T3 (da) 2002-01-17 2007-12-27 Novartis Ag Farmaceutiske sammensætninger indeholdende valsartan og NEP-inhibitorer
WO2004103993A1 (en) * 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP3067043B1 (en) 2007-11-06 2022-11-30 Novartis AG Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
PE20110943A1 (es) * 2009-01-28 2012-01-22 Novartis Ag Formulacion oral solida de alisquireno
WO2012027237A1 (en) 2010-08-24 2012-03-01 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
ES2879550T3 (es) 2012-08-24 2021-11-22 Novartis Ag Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares.
DK3038654T3 (da) 2013-08-26 2020-02-03 Novartis Ag Ny anvendelse
WO2015030711A1 (en) 2013-08-26 2015-03-05 Novartis Ag New use
ES3036922T3 (en) 2016-02-03 2025-09-25 Novartis Ag New use of a combination of sacubitril and valsartan

Also Published As

Publication number Publication date
WO2017134600A1 (en) 2017-08-10
JP6810152B2 (ja) 2021-01-06
RS67127B1 (sr) 2025-09-30
KR20180103940A (ko) 2018-09-19
CA3010778C (en) 2024-02-27
JP2019504096A (ja) 2019-02-14
US20240207227A1 (en) 2024-06-27
HUE072182T2 (hu) 2025-10-28
EP4609912A3 (en) 2025-11-12
JP2019504094A (ja) 2019-02-14
SI3411021T1 (sl) 2025-09-30
US20250325518A1 (en) 2025-10-23
CA3010778A1 (en) 2017-08-10
JP2023021991A (ja) 2023-02-14
AU2019280026A1 (en) 2020-01-16
DK3411021T3 (da) 2025-08-18
AU2017215530B2 (en) 2019-09-12
EP4609912A2 (en) 2025-09-03
WO2017134597A1 (en) 2017-08-10
FI3411021T3 (fi) 2025-07-31
PL3411021T3 (pl) 2025-09-08
JP7156945B2 (ja) 2022-10-19
JP2024160386A (ja) 2024-11-13
EP3411021B1 (en) 2025-05-14
HRP20250913T1 (hr) 2025-09-26
AU2017215530A1 (en) 2018-07-26
EP3411018A1 (en) 2018-12-12
CN108601741B (zh) 2022-05-24
US20190054069A1 (en) 2019-02-21
AU2019280026B2 (en) 2021-09-02
CN108601741A (zh) 2018-09-28
KR102805176B1 (ko) 2025-05-12
IL260955A (en) 2018-09-20
EP3411021A1 (en) 2018-12-12
PT3411021T (pt) 2025-08-06
ES3036922T3 (en) 2025-09-25

Similar Documents

Publication Publication Date Title
LT3411021T (lt) Sakubitrilo ir valsartano derinio naujas panaudojimas
LT3448386T (lt) Izochinolin-3-ilo karboksamidai ir jų gamyba bei naudojimas
IL261035A (en) Sulfonylureas, compounds close to them and their uses
LT3283107T (lt) Kompozicija apimanti ipilimumabo ir nivolumabo kombinaciją
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
LT3105253T (lt) Antikūnai prieš jagged1 ir jų naudojimo būdai
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
IL264813B (en) 2-oxo-imidazopyridines and their use
EP3532092A4 (en) IMMUNOGLOBULINS AND USES THEREOF
LT3126388T (lt) Antikūnai prieš egfrviii ir jų panaudojimo būdai
EP3102429C0 (en) ROLLING DEVICE, FURNITURE COMPRISING A ROLLING DEVICE AND USE OF THE ROLLING DEVICE
LT3128005T (lt) Sirp-alfa varianto konstruktai, ir jų panaudojimas
PT3543240T (pt) Inibidor de urat1 e utilização deste
LT3672948T (lt) Piridinamino-piridono ir pirimidinamino-piridono junginiai
LT3197898T (lt) Nauji imidazopiridazino junginiai ir jų panaudojimas
LT3337506T (lt) Deriniai ir jų panaudojimas
GB201617064D0 (en) Compounds and their therapeutic use
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
LT3231793T (lt) Dihidropirimidin-2-ono junginiai ir jų medicininis panaudojimas
LT3247711T (lt) Naujos scy-078 druskos ir polimorfai
LT3573611T (lt) Amidų junginiai ir jų naudojimas
LT3512849T (lt) 7-pakeistieji 1-aril-naftiridin-3-karboksamidai ir jų naudojimas
GB201421381D0 (en) A nematicidal composition and the use thereof
GB2533082C (en) A nematicidal composition and the use thereof